Midway Capital Research & Management Invests $1.20 Million in Pfizer Inc. $PFE

Midway Capital Research & Management bought a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 48,310 shares of the biopharmaceutical company’s stock, valued at approximately $1,203,000.

Several other hedge funds also recently bought and sold shares of PFE. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank raised its position in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its stake in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its stake in Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Morgan Stanley increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research note on Tuesday, June 9th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $28.82.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reaffirmed its 2026 guidance and said its strategic outlook remains intact, which should help limit downside if investors focus on fundamentals rather than the management change. Pfizer stock slides following CFO exit, 2026 guidance reaffirmed
• Positive Sentiment: The company moved quickly to appoint an interim finance chief, suggesting Pfizer has a planned transition process in place rather than a broader disruption to operations. Pfizer Announces Chief Financial Officer Transition
• Neutral Sentiment: News coverage also noted that Pfizer’s recent move is part of a broader investor debate about the company’s near-term growth catalysts and pipeline execution, rather than a change to its core business outlook. Reuters coverage of CFO departure
• Negative Sentiment: The biggest overhang is the unexpected departure of the CFO, which can create uncertainty about financial discipline and near-term investor confidence, helping explain why PFE has been declining. Pfizer CFO to leave company for consumer goods role

Pfizer Price Performance

NYSE PFE opened at $25.25 on Friday. The stock has a 50-day simple moving average of $26.22 and a 200 day simple moving average of $26.33. Pfizer Inc. has a twelve month low of $23.11 and a twelve month high of $28.75. The stock has a market capitalization of $143.94 billion, a PE ratio of 19.28 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the firm posted $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date was Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.